Home > Insider Trading > Filing (0001209191-19-025789)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1595893	Turning Point Therapeutics Inc.	TPTX	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1595117	Simeon George	C/O S.r.one, Limited 161 Washington Street, Suite 500 Conshohocken PA 19428		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-04-22	1,120,730	$0.00	1,120,730	No	4	C	Indirect	By S.R.One, Limited
Common Stock	Acquisiton	2019-04-22	546,820	$0.00	1,667,550	No	4	C	Indirect	By S.R.One, Limited
Common Stock	Acquisiton	2019-04-22	325,000	$18.00	1,992,550	No	4	P	Indirect	By S.R.One, Limited

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By S.R.One, Limited
No	4	C	Indirect	By S.R.One, Limited
No	4	P	Indirect	By S.R.One, Limited

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Acquisiton	2019-04-22	15,000	$0.00	15,000	$27.06
Common Stock	Series C Preferred Stock	Disposition	2019-04-22	4,314,809	$0.00	1,120,730	$0.00
Common Stock	Series D Preferred Stock	Disposition	2019-04-22	2,105,259	$0.00	546,820	$0.00

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
15,000	2029-04-21	No	4	A	Direct
0		No	4	C	Indirect
0		No	4	C	Indirect

Footnotes

Automatic conversion, in connection with the Issuer's initial public offering, of each share of preferred stock into 0.25974026 shares of common stock. The shares have no expiration date.
S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc, is the record holder of the shares reported herein. Simeon J. George holds the title of Vice President at S.R. One, Limited and is an employee of GlaxoSmithKline LLC, a wholly-owned subsidiary of GlaxoSmithKline plc. Mr. George disclaims beneficial ownership of all the shares held by S.R. One, Limited and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein.
The shares were purchased at the Issuer's initial public offering.
The option will become fully vested on the date of the Issuer's 2020 annual meeting of stockholders.
As a Vice President of S.R. One, Limited and an employee of GlaxoSmithKline LLC, Simeon George is obligated to transfer any shares issued under the stock option to S.R One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc.